# RXYLT1

## Overview
RXYLT1 is a gene that encodes the enzyme ribitol xylosyltransferase 1, which plays a pivotal role in the glycosylation process, specifically in the biosynthesis of O-mannosyl glycans. This enzyme is categorized as a glycosyltransferase and is involved in the formation of the GlcAβ1-4Xylβ1-4 unit, a critical component of the matriglycan structure on α-dystroglycan (α-DG) (Imae2021Biosynthetic). The proper function of ribitol xylosyltransferase 1 is essential for the binding of α-DG to extracellular matrix proteins, which is crucial for maintaining muscle cell integrity and facilitating neural cell migration (ENDO2019Mammalian). The enzyme operates within the Golgi apparatus, contributing to the maturation of glycoproteins (Kuwabara2020Crystal). Mutations in the RXYLT1 gene are associated with dystroglycanopathies, a group of disorders characterized by defects in glycosylation, leading to muscular and neurological symptoms (Kanagawa2021Dystroglycanopathy:).

## Structure


## Function
RXYLT1, also known as ribitol xylosyltransferase 1, is an enzyme involved in the glycosylation process, specifically in the biosynthesis of O-mannosyl glycans. It functions by adding a xylose to ribitol, forming a GlcAβ1-4Xylβ1-4 unit, which is a critical component of the laminin-binding epitope known as matriglycan on α-dystroglycan (α-DG) (Imae2021Biosynthetic). This glycan structure is essential for the binding of α-DG to matrix proteins, playing a crucial role in maintaining sarcolemmal stability and facilitating neural cell migration (Imae2021Biosynthetic).

RXYLT1 is active in the Golgi apparatus, where it contributes to the maturation of glycoproteins (Kuwabara2020Crystal). The enzyme's activity is vital for the proper function of α-DG, a component of the dystrophin-glycoprotein complex that links the extracellular matrix to the actin cytoskeleton. This linkage is important for muscle cell integrity and function (ENDO2019Mammalian). Defects in the glycosylation pathway involving RXYLT1 can lead to congenital muscular dystrophies, highlighting its significance in muscle health and development (Imae2021Biosynthetic).

## Clinical Significance
Mutations or dysfunctions in the RXYLT1 gene, previously known as TMEM5, are implicated in dystroglycanopathies, a group of disorders characterized by defects in the glycosylation of dystroglycan (DG). These conditions lead to a range of muscular and neurological symptoms due to the deficiency in matriglycan, a crucial component for DG's ligand binding activity (Kanagawa2021Dystroglycanopathy:). The enzyme encoded by RXYLT1, ribitol-5-phosphate xylosyltransferase 1, is involved in the synthesis of a linker structure between tandem ribitol-phosphate and matriglycan. Disruptions in this glycosylation pathway can result in muscular dystrophies, as the proper function of α-dystroglycan (α-DG) is compromised (Kanagawa2019Fukuyama).

The clinical spectrum of dystroglycanopathies associated with RXYLT1 mutations is broad, ranging from severe forms with muscular dystrophy and brain/eye abnormalities to milder forms like limb-girdle muscular dystrophy (ENDO2019Mammalian). Although specific diseases directly caused by RXYLT1 mutations are not explicitly mentioned, the gene's role in the glycosylation pathway suggests its potential contribution to these conditions (Kanagawa2018Ribitolphosphate—a). Understanding the clinical significance of RXYLT1 is crucial for diagnosing and managing related muscular dystrophies.


## References


[1. (ENDO2019Mammalian) Tamao ENDO. Mammalian &lt;i&gt;o&lt;/i&gt;-mannosyl glycans: biochemistry and glycopathology. Proceedings of the Japan Academy, Series B, 95(1):39–51, January 2019. URL: http://dx.doi.org/10.2183/pjab.95.004, doi:10.2183/pjab.95.004. This article has 44 citations.](https://doi.org/10.2183/pjab.95.004)

[2. (Kanagawa2019Fukuyama) Motoi Kanagawa, Hideki Tokuoka, and Tatsushi Toda. Fukuyama Congenital Muscular Dystrophy and Related Diseases, pages 209–221. Springer Singapore, 2019. URL: http://dx.doi.org/10.1007/978-981-13-2977-7_20, doi:10.1007/978-981-13-2977-7_20. This article has 0 citations.](https://doi.org/10.1007/978-981-13-2977-7_20)

[3. (Imae2021Biosynthetic) Rieko Imae, Hiroshi Manya, and Tamao Endo. Biosynthetic mechanisms and biological significance of glycerol phosphate-containing glycan in mammals. Molecules, 26(21):6675, November 2021. URL: http://dx.doi.org/10.3390/molecules26216675, doi:10.3390/molecules26216675. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/molecules26216675)

[4. (Kuwabara2020Crystal) Naoyuki Kuwabara, Rieko Imae, Hiroshi Manya, Tomohiro Tanaka, Mamoru Mizuno, Hiroki Tsumoto, Motoi Kanagawa, Kazuhiro Kobayashi, Tatsushi Toda, Toshiya Senda, Tamao Endo, and Ryuichi Kato. Crystal structures of fukutin-related protein (fkrp), a ribitol-phosphate transferase related to muscular dystrophy. Nature Communications, January 2020. URL: http://dx.doi.org/10.1038/s41467-019-14220-z, doi:10.1038/s41467-019-14220-z. This article has 24 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-019-14220-z)

[5. (Kanagawa2021Dystroglycanopathy:) Motoi Kanagawa. Dystroglycanopathy: from elucidation of molecular and pathological mechanisms to development of treatment methods. International Journal of Molecular Sciences, 22(23):13162, December 2021. URL: http://dx.doi.org/10.3390/ijms222313162, doi:10.3390/ijms222313162. This article has 31 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms222313162)

[6. (Kanagawa2018Ribitolphosphate—a) Motoi Kanagawa and Tatsushi Toda. Ribitol-phosphate—a newly identified posttranslational glycosylation unit in mammals: structure, modification enzymes and relationship to human diseases. The Journal of Biochemistry, 163(5):359–369, January 2018. URL: http://dx.doi.org/10.1093/jb/mvy020, doi:10.1093/jb/mvy020. This article has 20 citations.](https://doi.org/10.1093/jb/mvy020)